Alessandro Putzu1, Sara Clivio2, Alessandro Belletti3, Tiziano Cassina4. 1. Department of Cardiovascular Anesthesia and Intensive Care, Cardiocentro Ticino, Lugano, Switzerland. Electronic address: alessandroputzu@ymail.com. 2. Department of Cardiovascular Anesthesia and Intensive Care, Cardiocentro Ticino, Lugano, Switzerland. Electronic address: sara.clivio@cardiocentro.org. 3. Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. 4. Department of Cardiovascular Anesthesia and Intensive Care, Cardiocentro Ticino, Lugano, Switzerland. Electronic address: tiziano.cassina@cardiocentro.org.
Abstract
BACKGROUND: Several studies suggested beneficial effects of perioperative levosimendan on postoperative outcome after cardiac surgery. However, three large randomized controlled trials (RCTs) have been recently published and presented neutral results. We performed a systematic review with meta-analysis and trial sequential analysis (TSA) to assess benefits and harms of perioperative levosimendan therapy in cardiac surgery. METHODS: Electronic databases were searched up to September 2017 for RCTs on preoperative levosimendan versus any type of control. The Cochrane methodology was employed. We calculated odds ratio (OR) or Risk Ratio (OR) and 95% confidence interval (CI) using fixed-effects meta-analyses and we further performed TSA. RESULTS: We included data from 40 RCTs and 4246 patients. Pooled analysis of 5 low risk of bias trials (1910 patients) showed no association between levosimendan and mortality (OR 0.86 [95% CI, 0.62, 1.18], p=0.34, TSA inconclusive), acute kidney injury, need of renal replacement therapy, myocardial infarction, ventricular arrhythmias, and serious adverse events, but an association with higher incidence of supraventricular arrhythmias (RR 1.11 [95% CI, 1.00, 1.24], p=0.05, TSA inconclusive) and hypotension (RR 1.15 [95% CI, 1.01, 1.30], p=0.04, TSA inconclusive). Analysis including all 40 trials found that levosimendan was associated with lower postoperative mortality (OR 0.56 [95% CI, 0.44, 0.71], p<0.00001, TSA conclusive), acute kidney injury, and renal replacement therapy, and higher incidence of hypotension. CONCLUSIONS: There is not enough high-quality evidence to neither support nor discourage the systematic use of levosimendan in cardiac surgery.
BACKGROUND: Several studies suggested beneficial effects of perioperative levosimendan on postoperative outcome after cardiac surgery. However, three large randomized controlled trials (RCTs) have been recently published and presented neutral results. We performed a systematic review with meta-analysis and trial sequential analysis (TSA) to assess benefits and harms of perioperative levosimendan therapy in cardiac surgery. METHODS: Electronic databases were searched up to September 2017 for RCTs on preoperative levosimendan versus any type of control. The Cochrane methodology was employed. We calculated odds ratio (OR) or Risk Ratio (OR) and 95% confidence interval (CI) using fixed-effects meta-analyses and we further performed TSA. RESULTS: We included data from 40 RCTs and 4246 patients. Pooled analysis of 5 low risk of bias trials (1910 patients) showed no association between levosimendan and mortality (OR 0.86 [95% CI, 0.62, 1.18], p=0.34, TSA inconclusive), acute kidney injury, need of renal replacement therapy, myocardial infarction, ventricular arrhythmias, and serious adverse events, but an association with higher incidence of supraventricular arrhythmias (RR 1.11 [95% CI, 1.00, 1.24], p=0.05, TSA inconclusive) and hypotension (RR 1.15 [95% CI, 1.01, 1.30], p=0.04, TSA inconclusive). Analysis including all 40 trials found that levosimendan was associated with lower postoperative mortality (OR 0.56 [95% CI, 0.44, 0.71], p<0.00001, TSA conclusive), acute kidney injury, and renal replacement therapy, and higher incidence of hypotension. CONCLUSIONS: There is not enough high-quality evidence to neither support nor discourage the systematic use of levosimendan in cardiac surgery.
Authors: M Habicher; T Zajonz; M Heringlake; A Böning; S Treskatsch; U Schirmer; A Markewitz; M Sander Journal: Anaesthesist Date: 2018-05 Impact factor: 1.041
Authors: Anders Aneman; Nicholas Brechot; Daniel Brodie; Frances Colreavy; John Fraser; Charles Gomersall; Peter McCanny; Peter Hasse Moller-Sorensen; Jukka Takala; Kamen Valchanov; Michael Vallely Journal: Intensive Care Med Date: 2018-04-30 Impact factor: 17.440
Authors: Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello Journal: J Cardiovasc Pharmacol Date: 2020-07 Impact factor: 3.105
Authors: Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello Journal: Card Fail Rev Date: 2020-07-08
Authors: S Bouchez; F Fedele; G Giannakoulas; F Gustafsson; V-P Harjola; K Karason; M Kivikko; D von Lewinski; F Oliva; Z Papp; J Parissis; Piero Pollesello; G Pölzl; C Tschöpe Journal: Cardiovasc Drugs Ther Date: 2018-12 Impact factor: 3.727
Authors: Thomas W L Scheeren; Jan Bakker; Thomas Kaufmann; Djillali Annane; Pierre Asfar; E Christiaan Boerma; Maurizio Cecconi; Michelle S Chew; Bernard Cholley; Maria Cronhjort; Daniel De Backer; Arnaldo Dubin; Martin W Dünser; Jacques Duranteau; Anthony C Gordon; Ludhmila A Hajjar; Olfa Hamzaoui; Glenn Hernandez; Vanina Kanoore Edul; Geert Koster; Giovanni Landoni; Marc Leone; Bruno Levy; Claude Martin; Alexandre Mebazaa; Xavier Monnet; Andrea Morelli; Didier Payen; Rupert M Pearse; Michael R Pinsky; Peter Radermacher; Daniel A Reuter; Yasser Sakr; Michael Sander; Bernd Saugel; Mervyn Singer; Pierre Squara; Antoine Vieillard-Baron; Philippe Vignon; Jean-Louis Vincent; Iwan C C van der Horst; Simon T Vistisen; Jean-Louis Teboul Journal: Ann Intensive Care Date: 2021-01-29 Impact factor: 6.925
Authors: D Beitzke; F Gremmel; D Senn; R Laggner; A Kammerlander; A Wielandner; R Nolz; M Hülsmann; C Loewe Journal: Int J Cardiovasc Imaging Date: 2020-10-24 Impact factor: 2.357